GET DAILY SIGNALSReplimune Group (REPL) Eyes Further Gains Toward the $22 Analyst Target
Key Takeaways
- The central $22 stock price target is the arithmetic mean of seven verified analyst price targets, rounded from roughly $21.86.
- At a recent price near $19.49, reaching $22 requires a further gain of about 12.9%, a modest move by this stock's recent standards.
- The analyst range is unusually wide, from a low of $14 (Piper Sandler) to a high of $31 (Leerink Partners), reflecting genuine disagreement about commercial execution.
- The strongest supports are the FDA's accelerated approval of TUDRIQEV for advanced melanoma and early prescribing traction across more than 15 institutions.
- The biggest risks are an unproven commercial launch, persistent operating losses, share dilution, elevated short interest, and outstanding securities litigation.
- You can explore this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For a broader, AI-driven view of market opportunities, explore Trending AI Robots.
What the Analyst Targets Reveal
The $22 central target reflects seven individual targets from named firms. The most recent updates followed the company's fiscal second-quarter 2027 report, with Jefferies analyst Roger Song raising his target to $29 from $24 (Buy) and Leerink Partners lifting its to $31 from $19 (Outperform). Other firms include J.P. Morgan at $21, BMO Capital and Wedbush at $19, Kempen & Co at $19, and Piper Sandler at $14. The simple average of these seven figures comes to about $21.86, which rounds to $22.
This mean is not a formal published consensus, and the spread remains wide. Bullish firms see the melanoma franchise scaling quickly enough to support a premium valuation, while more cautious voices highlight the clinical-stage balance sheet and a launch that has yet to produce meaningful revenue. The $14-to-$31 range shows how much of the debate centers on unproven sales rather than near-term financials. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where the Stock Stands Today
Replimune Group, Inc. (REPL) closed near $19.49 on November 2, 2026, within a whisker of its 52-week high. Reaching $22 would require roughly a 12.9% gain — modest relative to the stock's recent volatility, but not automatic. The company remains unprofitable, with no trailing revenue and a net loss of roughly $57.1 million in its latest quarter.
The path to $22 therefore runs through commercial execution. Replimune's first product, TUDRIQEV (vusolimogene oderparepvec, or RP1), received FDA accelerated approval for adults with advanced melanoma who have progressed on a PD-1-based regimen, and is administered in combination with nivolumab. The company reported that more than 15 institutions had begun prescribing the drug, that it had contacted over 70% of its first 200 target accounts, and that cash of about $307.8 million provides a runway of more than 12 months.
Factors That Could Drive It Higher
Several elements could support further upside. The FDA approval shifted Replimune from a binary clinical-stage story into a company with an actual marketed therapy, and early signs of formulary access and prescribing activity suggest demand is materializing. A narrower-than-expected quarterly loss also signals improving expense discipline. Bullish analysts see a sizable market opportunity in advanced melanoma and a pipeline (RP2, RP3) that could broaden the platform. Positive analyst revisions, with multiple firms raising targets in recent weeks, have reinforced upward momentum.
Risks That Could Hold It Back
The principal obstacle is that the commercial launch is still unproven. Revenues have yet to materialize, and Replimune competes against established melanoma treatments. The company is loss-making and has relied on equity financing, including a roughly $150 million offering in August 2026, which can dilute existing shareholders. Elevated short interest of roughly 24% of the float suggests meaningful skepticism, and several securities class action lawsuits were filed following the stock's earlier collapse. A slower-than-expected launch, disappointing pricing, or a regulatory setback could pressure the valuation.
Technical Picture and Key Levels
The stock trades far above its 50-day moving average near $13.60 and its 200-day moving average near $9.35, and its RSI (relative strength index, a momentum gauge) sits above 70, a zone often associated with overbought conditions. The shares recently broke decisively above the $16-to-$18 range to make new 52-week highs, leaving the $17-to-$18 area as a potential support zone on any pullback, while the round $20 level and the prior high near $19.68 represent near-term resistance between the current price and $22.
What to Watch Going Forward
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms differ, and the wide $14-to-$31 range means the appropriate time frame is uncertain. Investors should watch quarterly revenue disclosures for the first hard evidence of TUDRIQEV sales, prescribing and formulary metrics, cash-burn trends, any additional financing, and further analyst revisions. Regulatory updates on the confirmatory trials and pipeline readouts will also matter for the long-term valuation.
Leveraging AI Tools in Volatile Names
One tool I turn to regularly for names like this is Tickeron's AI Daily Buy/Sell Signals. It uses artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile stock such as Replimune, these signals can help identify changes in momentum and manage positions more systematically, allowing traders to spot opportunities, track holdings, and respond to evolving trends with greater efficiency.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 185 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.417) is normal, around the industry mean (3.104). P/E Ratio (-6.556) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement